Lenva 4 mg (Lenvatinib) Capsules

Lenva 4 mg (Lenvatinib) is a targeted anticancer medicine used in the management of specific types of advanced or progressive cancers. It works by blocking certain proteins involved in tumor growth and the formation of new blood vessels that supply cancer cells. This targeted action may help slow disease progression and support overall treatment outcomes. It is commonly prescribed for selected patients with thyroid cancer, hepatocellular carcinoma (liver cancer), renal cell carcinoma (kidney cancer), and endometrial cancer under specialist supervision. Treatment decisions should always be based on individual patient assessment and clinical guidelines.

Each capsule contains Lenvatinib Mesylate equivalent to Lenvatinib 4 mg as the active pharmaceutical ingredient. Lenvatinib belongs to a class of medicines known as multi-targeted tyrosine kinase inhibitors (TKIs). The formulation may also contain pharmaceutical-grade inactive ingredients that help maintain capsule stability, effectiveness, and quality. The medicine is designed for oral administration and should be used only as directed by a qualified healthcare professional experienced in cancer treatment.

Lenva 4 mg capsules should be taken exactly as prescribed by an oncologist or healthcare provider. The dosage may vary depending on the type of cancer being treated, the patient's overall health condition, body weight, and response to therapy. Capsules are generally swallowed whole with water and may be taken with or without food. Patients should take the medicine at approximately the same time each day to maintain consistent blood levels. If a dose is missed, follow the advice of the treating physician or the approved prescribing information. Do not adjust, stop, or restart treatment without medical guidance, as dosage modifications may be required based on treatment response or side effects.